Author: Dev
![Zeotap launches Google Customer Match integration to drive addressability in a post-cookie world Zeotap launches Google Customer Match integration to drive addressability in a post-cookie world](https://www.newscienceventures.com/wp-content/uploads/2017/10/Zeotap-new.png)
Zeotap launches Google Customer Match integration to drive addressability in a post-cookie world
Zeotap, the leading Customer Data Platform, has launched a new integration with Google Customer Match, enabling marketers to leverage their first-party data to engage audiences at scale across Google Search, Shopping, Gmail, YouTube and Display. In doing so, the new integration provides an important solution to addressability when third-party cookies
Read More![CanCell Therapeutics partners with Ovizio to improve monitoring of CAR-T cell production CanCell Therapeutics partners with Ovizio to improve monitoring of CAR-T cell production](https://www.newscienceventures.com/wp-content/uploads/2020/11/ovizio16680.jpg)
CanCell Therapeutics partners with Ovizio to improve monitoring of CAR-T cell production
Ovizio Imaging Systems, a manufacturer of cell analyzers for advanced monitoring in the bioprocessing market, and CanCell Therapeutics, an early-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that they will enter into a collaboration to further improve the monitoring of CAR-T cell-therapy manufacturing. The partnership
Read More![Zeotap launches Predictive Audiences to empower marketers with machine learning Zeotap launches Predictive Audiences to empower marketers with machine learning](https://www.newscienceventures.com/wp-content/uploads/2017/10/Zeotap-new.png)
Zeotap launches Predictive Audiences to empower marketers with machine learning
Zeotap the leading Customer Data Platform, has today announced the launch of Predictive Audiences as part of its award-winning Customer Intelligence Platform (CIP). Designed to help marketing users increase the impact of their campaigns, it enables the creation and application of machine-learned predictive segments in just a few clicks. Predictive
Read More![Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial](https://www.newscienceventures.com/wp-content/uploads/2020/11/vt98.jpg)
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal
Read More![Zeotap builds momentum as marketing industry shifts away from cookies Zeotap builds momentum as marketing industry shifts away from cookies](https://www.newscienceventures.com/wp-content/uploads/2017/10/Zeotap-new.png)
Zeotap builds momentum as marketing industry shifts away from cookies
Zeotap, the Customer Intelligence Platform (CIP), has reported 126% ARR growth in 2020 among its latest milestones in growth. Building momentum from its $60.5 million Series C fundraising round last year, the company is capitalizing on the marketing industry’s move to better engage first-party data in the face of the
Read More![Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases](https://www.newscienceventures.com/wp-content/uploads/2020/11/ventyx.png)
Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases
Ventyx Biosciences, Inc. a clinical-stage biotechnology company developing oral, small molecule therapeutics for autoimmune disease, today announced the dosing of the first subject in a Phase 1 clinical trial of VTX-958, a novel and selective allosteric TYK2 inhibitor. In non-clinical studies, VTX-958 has shown potential to treat autoimmune diseases by
Read More![TigerConnect acquires Critical Alert TigerConnect acquires Critical Alert](https://www.newscienceventures.com/wp-content/uploads/2020/11/tigerconnect.png)
TigerConnect acquires Critical Alert
TigerConnect®, healthcare’s most advanced, reliable, and widely adopted care team collaboration solution, today announced the acquisition of Critical Alert®, a leading provider of enterprise-grade middleware for hospitals and health systems. Critical Alert’s product suite consists of a middleware suite of products as well as traditional nurse call hardware servicing over
Read More![Amarisoft and Dali Wireless Collaborate to Deliver Open RAN Based 4G and 5G Solutions Amarisoft and Dali Wireless Collaborate to Deliver Open RAN Based 4G and 5G Solutions](https://www.newscienceventures.com/wp-content/uploads/2020/11/2122-1.png)
Amarisoft and Dali Wireless Collaborate to Deliver Open RAN Based 4G and 5G Solutions
Interoperability and co-marketing initiatives will bring new options for enterprises, and mobile network operators deploying in-building cellular solutions Menlo Park, California and Paris, France – February 11, 2020 – Dali Wireless, a global leader in wireless fronthaul innovation for virtual RAN, and Amarisoft, a pioneer in software centric 4G LTE
Read More![ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital](https://www.newscienceventures.com/wp-content/uploads/2020/11/proterix.png)
ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital
Billerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by researchers at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University which is a joint
Read More![Perceptimed Awarded NIH Development Grant Perceptimed Awarded NIH Development Grant](https://www.newscienceventures.com/wp-content/uploads/2020/11/percptimed.png)
Perceptimed Awarded NIH Development Grant
PERCEPTIMED AWARDED $1.5M NIH DEVELOPMENT GRANT MOUNTAIN VIEW, CA – PerceptiMed, Inc., was awarded a $1.5 million grant from the National Institutes of Health (NIH) to develop and test a secure, individual medication system for long-term care facilities. Dr. Alan Jacobs, CEO and founder of PerceptiMed will serve as
Read More![Perceptimed Founder Jacobs To Speak At Bio2device Group Event Perceptimed Founder Jacobs To Speak At Bio2device Group Event](https://www.newscienceventures.com/wp-content/uploads/2020/11/percptimed.png)
Perceptimed Founder Jacobs To Speak At Bio2device Group Event
PERCEPTIMED FOUNDER JACOBS TO SPEAK AT BIO2DEVICE GROUP EVENT MOUNTAIN VIEW, CA – April 25, 2014 – “Preventing Drug-Related Patient Injury and Death with Advanced, Cost-Effective Technology” is the topic Alan Jacobs, M.D., Ph.D., CEO and founder of PerceptiMed, will address at the Bio2Device lecture. The lecture will take place
Read More![2019: A Look Back 2019: A Look Back](https://www.newscienceventures.com/wp-content/uploads/2020/11/Logo_GTxcel.jpg)
2019: A Look Back
2019 was an exciting and busy year for us! As we take a look back at some of our milestones, we’d like to give a big thank you to all of our publishers. We’re looking forward to what’s in store in the coming year! We’re happy to report that 2019
Read More